Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of iptacopan in C3 glomerulopathy
MOH_2021-11-30_010437Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) comparing Iptacopan arm with Placebo arm (2 arms). Primary endpoints: Reduction in urine protein-creatinine ratio, Improvement in estimated glomerular filtration rate and 1 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on MOH_2021-11-30_010437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-30_010437.